Horizon Pharma has agreed to purchase Hyperion Therapeutics for $955.7 million in cash, in a move to expand its drug portfolio by adding two treatments for a rare metabolic condition.
from WSJ.com: US Business http://ift.tt/19zFlLE
via IFTTT
from WSJ.com: US Business http://ift.tt/19zFlLE
via IFTTT
No comments:
Post a Comment